Quince Therapeutics Seeks Shareholder Approval for Second Reverse Stock Split (Up to 1-for-100) Amid Delisting Threats
QNCX sits 59% above its 52-week low of $0.8 on light trading volume (0.1× avg).
Summary
Quince Therapeutics filed a definitive proxy statement for its annual meeting on June 11, 2026, seeking approval for a highly aggressive reverse stock split (1-for-10 to 1-for-100) to address Nasdaq listing deficiencies, following a 1-for-10 split just weeks prior.
Key Events · Corporate Governance and Compliance · QNCX
-
Shareholder Meeting Scheduled
The Annual Meeting of Stockholders is scheduled for Thursday, June 11, 2026, where key proposals will be voted upon.
-
Proposal for Second Reverse Stock Split
Shareholders will vote on an amendment to the certificate of incorporation to effect a reverse stock split with a ratio ranging from 1-for-10 to 1-for-100.
-
Follows Recent 1-for-10 Reverse Split
This proposal comes after the company already effected a 1-for-10 reverse stock split on April 10, 2026, which became effective on Nasdaq on April 13, 2026.
-
Addresses Nasdaq Listing Compliance
The proposed reverse split is primarily intended to regain and maintain compliance with Nasdaq's minimum $1.00 bid price requirement.
Analysis · QNCX · Life Sciences
Quince Therapeutics has filed a definitive proxy statement for its annual meeting on June 11, 2026, where shareholders will vote on a proposal to effect a highly aggressive reverse stock split, ranging from 1-for-10 to 1-for-100. This comes just weeks after the company already executed a 1-for-10 reverse stock split on April 10, 2026. The repeated need for such a drastic measure underscores the company's severe financial distress and its ongoing struggle to maintain compliance with Nasdaq's minimum bid price requirement. The filing also explicitly states that this proposed reverse split will not address the separate Nasdaq deficiency related to the Market Value of Listed Securities (MVLS). Given the prior disclosure of a 'going concern' warning and the pursuit of a reverse merger, this definitive proxy statement highlights the critical nature of the company's efforts to remain publicly listed and potentially facilitate a strategic transaction, signaling significant risk and potential further dilution for investors.
At the time of this filing, QNCX was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21M. The 52-week trading range was $0.80 to $45.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.